Sema4 and BioSymetrics have formed a strategic partnership to accelerate the advancement of new medicines for patients and pharmaceutical companies. The partnership will leverage Centrellis®, Sema4’s proprietary health intelligence platform, and Elion, BioSymetrics’ phenotypic drug discovery platform.
“We’re excited to work closely with BioSymetrics to discover higher value, de-risked drug candidates for patients,” said Eric Schadt, PhD, Founder and CEO, Sema4. “The power of applying our predictive network modeling to drug discovery will result in greater success, lower attrition, and a deeper understanding of the patient journey as it relates to identifying more personalized treatments.”